ParaMet (A systematic analysis of parasite metabolism – from metabolism to intervention) is a Marie Curie Initial Training Network funded by the European Commission and currently involves 12 scientific and industrial partners from 6 European countries. The project is coordinated by Professor Sylke Müller at the University of Glasgow, UK with the administrative support of Gillian Murray and her team.
ParaMet will train a new generation of European scientists (Experienced and Early Stage Researchers) in the requisites of preclinical drug discovery, combining academic excellence in innovation with industrial rigor and thus providing inter-disciplinary training from an academic and industrial perspective.
1st Annual Meeting, Arcachon (ERs, ESRs and PIs) 12 PhD Scholarships and 2 Postdoctoral positions are funded by the Marie Curie Initial Training Network to study parasite metabolism and to contribute to drug discovery against neglected tropical diseases and malaria
Please click on one of the markers on the map of Europe to see where our collaborators are based, what projects they are working on and to be able to click through to their individual profiles.
Dissecting the link between cytosolic and mitochondrial glucose metabolism in Plasmodium falciparum
Systems analysis of the role of protein kinases in trypanosome metabolic regulation
The metabolic consequences of perturbation to the pentose phosphate pathway in trypanosomes and Leishmania
Discovering the epigenetic-metabolic interface in Plasmodium
Modelling apicomplexan metabolic and transcriptional regulatory networks
Identification of new metabolic pathways in trypanosomatids
Drug target identification in Trypanosoma brucei using an over-expression library
Metabolic consequences of gene knockout in Trypanosomes
Genome-Scale Reconstruction and study of Trypanosoma metabolism from a Systems Biology perspective
Characterisation of unexplored key steps of phospholipid metabolism in Plasmodium and their potential use as pharmacological targets
Exploring pyrimidine metabolism in Trypanosoma brucei and identification of natural products with antitrypanosomal activity
Identification of natural products against malaria and kinetoplastid diseases
Cyclin-dependent kinases of Eimeria as drug targets
Establishment of the target metabolic pathways of new antitrypanosomal
Medivir is a pharmaceutical company dedicated to discovery and development of potential therapeutic agents